- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02676609
Impact of Food Carbohydrate and Insulin Dose Computing by on Smart Phone on Glucose Control in Patients With Diabetes (GLUCAL)
Assessment of the Impact of Food Carbohydrate and Insulin Dose Computing by an Application on Smart Phone on Glucose Control in Patients With Type 1 Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hérault
-
Montpellier, Hérault, France, 34000
- Hôpital Lapeyronie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 1 diabetes since more than 1 year
- Basal-bolus insulin regimen since more than 6 months
- Daily practice of food carbohydrate counting since more than 6 months
- HbA1c level below 12%
Exclusion Criteria:
- Type 2 diabetes
- No ability to use a smart phone
- Pregnancy or lactation
- Severe psychiatric disorders
- Eating disorders
- Alcohol abuse or recreational drug use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Use of smart phone application (device glucal)
Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio. During the first month, then during the second month they'll use as usual their traintement and meal without the apllication |
Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
|
Active Comparator: Use of smart phone application (second month)
During the first month they'll use as usual their traintement and meal without the apllication ,then during the second month they'll use the apllicatioin. Before each meal patient will enter in the application food intakes. Automated carbohydrate and meal insulin dose computing according to individual meal insulin/carbohydrate ratio. |
Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
2-hour postmeal blood glucose values between 80 and 180 mg/dl
Time Frame: 4 weeks
|
Percent 2-hour postmeal blood glucose values between 80 and 180 mg/dl during 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean 2-hour postmeal blood glucose level
Time Frame: 4 weeeks
|
Average 2-hour postmeal blood glucose level during 4 weeks
|
4 weeeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Eric RENARD, MD, PhD, University Hospital, Montpellier
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF 9665
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Automated carbohydrate and meal insulin dose computing
-
McGill University Health Centre/Research Institute...RecruitingDiabetes Mellitus, Type 1 | Type 1 DiabetesCanada
-
University of MinnesotaCompleted
-
University of British ColumbiaMitacsCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Withdrawn
-
Weill Medical College of Cornell UniversityCompletedType 2 DiabetesUnited States
-
Universitat Politècnica de ValènciaHospital Clínico Universitario de ValenciaNot yet recruiting
-
Northumbria UniversityCompletedLow Fat Meal - Unadjusted Insulin Dose | High Fat Meal - Unadjusted Insulin Dose | High Fat Meal - Adjusted Insulin Dose +30 Percent | High Fat Meal - Adjusted Insulin Dose +Split Dose
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... and other collaboratorsCompleted
-
Khyber Medical University PeshawarRecruitingObesity, OverweightPakistan
-
University of CambridgeCambridge University Hospitals NHS Foundation TrustCompletedType 1 DiabetesUnited Kingdom